single-dose pen “amidst the dangers of fake or illegitimate compounded 'semaglutide,'" the company noted in its March 5 press release. "Novo Nordisk continues to advance solutions for patients ...

Novo Nordisk A/S, together with its subsidiaries ... The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes ...

Diabetes specialist Novo Nordisk is feeling the heat from increasingly ... innovation in insulin products and user-friendly insulin pen devices. The company also expanded into haemophilia and ...

Novo Nordisk increased R&D investments from 13.6% in 2022 to 14.0% in 2023. The company also announced that it would be expanding its presence in the pen needles market through a research hub in ...

The company has introduced two new liraglutide injectable pens to the UK market ... Liraglutide, initially sold by Denmark’s Novo Nordisk (NOV: N) under the brand names Victoza and Saxenda, among ...

Novo Nordisk’s attempt to create a successor to its weight loss blockbuster Wegovy may have taken a hit with recent ...

Victoza is Novo Nordisk’s once-daily injectable GLP-1 agonist and made around $3.6 billion in sales last year, making it the top-selling drug in the category.

Most people would probably prefer a pill to a needle. Indeed, the stakes are high. Novo Nordisk recently suffered a setback with CagriSema, its next-generation injectable drug in testing to treat ...

Pharmaceutical giant Novo Nordisk (NYSE: NVO ... Most people would probably prefer a pill to a needle.

It has maintained its global diabetes value market share over the past year at 33.7%, fueled by Rybelsus, Ozempic and Victoza, putting up a strong performance. In 2024, Novo Nordisk’s GLP-1 ...